Results 301 to 310 of about 16,336,802 (316)

Open-label nondeceptive placebos

Open-label placebos (OLPs), where patients are informed they are receiving a placebo, challenge the traditional notion that placebos require deception to be effective. Recent research has shown that OLPs can positively impact subjective outcomes, such as pain perception and symptom severity, across various conditions like chronic pain, mental disorders,
Julian, Kleine-Borgmann, Ulrike, Bingel
openaire   +2 more sources

Open‐label use of placebos in the treatment of ADHD: a pilot study

Child: Care, Health and Development, 2007
AbstractBackground This study examined short‐term efficacy, side effects and acceptability of a placebo treatment procedure designed to maintain children with attention deficit hyperactivity disorder (ADHD) on 50% of their usual stimulant dose.Methods An open‐label prospective crossover trial was conducted in 26 children with ADHD, ages 7–15 years ...
A D, Sandler, J W, Bodfish
openaire   +2 more sources

Open-label nondeceptive placebo analgesia is blocked by the opioid antagonist naloxone

Pain, 2022
Abstract Open-label placebos, or placebos without deception, have been found to induce analgesia, a challenging concept that need to be investigated in detail. In particular, what we need to know is the mechanism through which analgesia is induced when no deception is involved. In this study, we show for the first time that open-label placebo
Benedetti F., Shaibani A., Arduino C., Thoen W.   +3 more
openaire   +2 more sources

Open-Label placebo for the treatment of unipolar depression: Results from a randomized controlled trial.

Journal of Affective Disorders, 2020
BACKGROUND The response to placebo is robust in studies of various antidepressant treatments. The strong placebo response, combined with the absence of side-effects, has prompted suggestions to use the ethically sound open-label placebo (OLP) as a ...
U. Nitzan, Gal Carmeli, Yossi Chalamish, Y. Braw, I. Kirsch, D. Shefet, I. Krieger, S. Mendlovic, Y. Bloch, P. Lichtenberg   +9 more
semanticscholar   +1 more source

Children's and parents' perspectives on open‐label use of placebos in the treatment of ADHD

Child: Care, Health and Development, 2007
AbstractBackground  The purpose of this study was to examine the efficacy and acceptability of an open‐label conditioned placebo dose reduction (CPDR) treatment in 70 children with attention deficit hyperactivity disorder (ADHD). This paper focuses on the qualitative data from the study.Methods  Following a double‐blind, crossover dose finding ...
A, Sandler, C, Glesne, G, Geller
openaire   +2 more sources

Worth a try – A survey on the general acceptance of open-label placebos

Journal of Psychosomatic Research, 2023
Forkmann, Katarina, Müßgens, Diana, Hashim, Ashtar, Bingel, Ulrike   +3 more
openaire   +3 more sources

Time to reflect on open-label placebos and their value for clinical practice

Pain, 2023
Caitlin M.P. Jones, Chung-Wei Christine Lin, Charlotte Blease, Jen Lawson, Christina Abdel Shaheed, Christopher G. Maher   +5 more
openaire   +2 more sources

Enthusiastic claims for open-label placebo pills ignore the evidence

Pain, 2020
Anita B, Amorim, Gustavo C, Machado, Chris G, Maher   +2 more
openaire   +2 more sources

The Use of Conditioning Open-Label Placebo in Opioid Dose Reduction: A Case Report and Literature Review

Frontiers in Pain Research, 2021
Jeffrey Schneider, M Anayali Estudillo-Guerra, Leon Morales-Quezada   +2 more
exaly  

From Placebo to 'Open-Label Placebo' to Open Altogether

2014
Mommaerts, Jean-Luc, Devroey, Dirk
openaire   +1 more source